Skip to main content

Table 1 Correlation of PRCC expression and clinical features of HCC patients

From: PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma

Variables

Low (n = 33)

High (n = 33)

P-value

Gender, n (%)

  

0.741

 Female

6 (18.2)

5 (15.2)

 

 Male

27 (81.8)

28 (84.8)

 

Age, n (%)

  

0.218

 ≤ 50

14 (42.4)

19 (57.6)

 

 > 50

19 (57.6)

14 (42.4)

 

HBV, n (%)

  

0.689

 Negative

4 (12.1)

3 (9.1)

 

 Positive

29 (87.9)

30 (90.9)

 

Cirrhosis, n (%)

  

0.689

 No

4 (12.1)

3 (9.1)

 

 Yes

29 (87.9)

30 (90.9)

 

AFP, n (%)

  

0.032

 Negative, < 20 µg/L

14 (42.4)

6 (18.2)

 

 Positive, ≥ 20 µg/L

19 (57.6)

27 (81.8)

 

Tumor size, n (%)

  

0.398

 ≤ 3 cm

10 (30.3)

7 (21.2)

 

 > 3 cm

23 (69.7)

26 (78.8)

 

Tumor number, n (%)

  

0.492

 = 1

6 (18.2)

4 (12.1)

 

 > 1

27 (81.8)

29 (87.9)

 

PVTT, n (%)

  

0.046

 No

6 (18.2)

1(3.0)

 

 Yes

27 (81.8)

32 (97.0)

 

TNM stage, n (%)

  

0.030

 I and II

10 (30.3)

3 (9.1)

 

 III and IV

23 (69.7)

30 (90.9)